Bladder Cancer Clinical Cohorts

Cisplatin-based chemotherapy is the standard of care for patients with muscle invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, and some patients with metastatic disease achieve complete responses to these therapies. However, the molecular determinants of cisplatin response are incompletely understood. We performed whole exome sequencing on tumor and germline DNA from patients with muscle invasive or metastatic urothelial carcinoma who received cisplatin-based chemotherapy to identify somatic mutations that occurred preferentially in cisplatin responders.]]>
Samples were collected from patients in the IRB-approved studies. For inclusion, patients had to have received complete course of a neoadjuvant or metastatic cisplatin-based chemotherapy regimen as per standard clinical practice.]]>